ROLE OF ADJUVANT INTRAVESICAL CHEMOTHERAPY IN THE COMBINED ORGAN-SPARING TREATMENT OF NON-MUSCLE-INVASIVE BLADDER CANCER

Objective: to enhance the efficiency of combined treatment for non-muscle-invasive bladder cancer ((NMIBC) and to assess the results of its treatment using transurethral resection (TUR) as monotherapy and in combination with intravesical adjuvant chemotherapy (CT).

Subjects and methods. The results of treatment were analyzed in 59 patients with NMIBC. Twenty-two patients underwent TUR in Group 1; TUR and single intravesical injection of drugs were performed in 19 patients in Group 2; 18 patients had TUR and long-term intravesical CT.

Results and discussion. The recurrence rates were 59.1, 57.9, and 38.89 % in Groups 1, 2, and 3, respectively. Intravesical CT was found to appreciably affect the prevention of recurrence in the area of resection. The rate of this recurrence was 31.81, 26.32, and 5.56 % in Groups 1, 2, and 3, respectively.

 Conclusion. Adjuvant intravesical chemotherapy CT is an effective method to prevent recurrent bladder cancer.